New Delhi, Jan 25 (PTI) Strides Pharma Science on Thursday said its subsidiary has received approval from the US health regulator for a generic medication for nerve pain.

Singapore-based Strides Pharma Global Pte has received approval for Pregabalin capsules from the US Food & Drug Administration (USFDA), the drug maker said in a regulatory filing.

Also Read | Republic Day Parade 2024 Full Schedule With Time: From Chief Guest to Theme and Routes, Know All About 75th Republic Day of India Celebrations at Kartavya Path.

The company's product is bio-equivalent and therapeutically equivalent to the reference listed drug -- Lyrica capsules -- used in the treatment of fibromyalgia.

As per IQVIA data, Pregabalin capsules have a market size of USD 248 million in the US market.

Also Read | Republic Day 2024 Chief Guest Is French President Emmanuel Macron, Check List of Chief Guests Who Visited India in the Last 5 Years.

Shares of Strides Pharma Science on Thursday ended 2.27 per cent up at Rs 685.75 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)